WP
WPS.F West Pharmaceutical Services Inc
- Market cap
- EUR 25.7B
- P/E
- 48.1x
- P/B
- 9.67x
- ROE
- 22.8%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is WPS.F undervalued?
Graham numberThe Graham number of West Pharmaceutical Services Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
West Pharmaceutical Services Inc fundamental analysis
No fundamental analysis for West Pharmaceutical Services Inc yet.
West Pharmaceutical Services Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of inje…
Full company profileWest Pharmaceutical Services Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
West Pharmaceutical Services Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.51B | 1.60B | 1.72B | 1.84B | 2.15B | 2.83B | 2.89B | 2.95B | 2.89B | 3.07B | 3.46B |
| Gross Profit | 501M | 513M | 545M | 606M | 768M | 1.18B | 1.14B | 1.13B | 999M | 1.10B | 1.30B |
| Operating Income | 228M | 238M | 248M | 305M | 407M | 752M | 734M | 707M | 591M | 636M | 786M |
| EBITDA | - | 327M | 354M | 404M | 519M | 878M | 855M | 844M | 744M | 773M | 1.03B |
| Net Income | 144M | 151M | 207M | 242M | 346M | 662M | 586M | 593M | 493M | 494M | 676M |
| EPS | - | 2.04 | 2.79 | 3.26 | 4.68 | 8.93 | 7.91 | 8.07 | 6.81 | 6.85 | 9.68 |
| Balance Sheet | |||||||||||
| Total Assets | 1.72B | 1.86B | 1.98B | 2.34B | 2.79B | 3.31B | 3.62B | 3.83B | 3.64B | 4.27B | 4.06B |
| Total Liabilities | 599M | 583M | 583M | 768M | 939M | 978M | 932M | 949M | 961M | 1.09B | 1.09B |
| Shareholders' Equity | 1.12B | 1.28B | 1.40B | 1.57B | 1.85B | 2.34B | 2.68B | 2.88B | 2.68B | 3.18B | 2.97B |
| Cash & Short-term Investments | 203M | 236M | 337M | 439M | 616M | 763M | 894M | 854M | 485M | 791M | 464M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 219M | 263M | 289M | 367M | 473M | 584M | 724M | 768M | 653M | 755M | 538M |
| Capital Expenditure | 170M | 131M | 105M | 126M | 174M | 253M | 285M | 348M | 377M | 286M | 167M |
| Free Cash Flow | - | 133M | 184M | 241M | 298M | 584M | 439M | 420M | 276M | 469M | 371M |
| Ratios | |||||||||||
| ROE | 12.9% | 11.8% | 14.8% | 15.4% | 18.7% | 28.3% | 21.8% | 20.6% | 18.4% | 15.5% | 22.8% |
| ROA | 8.4% | 8.1% | 10.5% | 10.3% | 12.4% | 20.0% | 16.2% | 15.5% | 13.5% | 11.6% | 16.6% |
| Net Profit Margin | 9.5% | 9.4% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% | 19.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
West Pharmaceutical Services Inc dividends
- Dividend yield
- 0.25%
- Forward dividend
- 0.93 EUR
- Payout ratio
- 12.4%
- Ex-dividend date
- Nov 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 61.2M | 0.85 | 12.4% |
| 2024 | USD 59.1M | 0.82 | 12.0% |
| 2023 | USD 56.3M | 0.77 | 9.5% |
| 2022 | USD 54.1M | 0.73 | 9.2% |
| 2021 | USD 51.1M | 0.69 | 7.7% |
| 2020 | USD 48.1M | 0.65 | 13.9% |
| 2019 | USD 45.1M | 0.61 | 18.7% |
| 2018 | USD 42.1M | 0.57 | 20.3% |
| 2017 | USD 39.1M | 0.53 | 25.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Sep 27, 2013.
Who owns West Pharmaceutical Services Inc
- Insiders 0.66%
- Institutions 99.34%
- Public & others 0.00%
- Shares outstanding 69.7M
- Free float 69.1M
West Pharmaceutical Services Inc company profile
- Company name
- West Pharmaceutical Services Inc
- Ticker
- WPS.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10,000
- Fiscal year end
- December
- Address
- 530 Herman O. West Drive, Exton, PA, United States, 19341-1147
- Phone
- 610 594 2900
- Website
- westpharma.com
About West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services Inc management
10- Mr. Robert W. McMahon C.M.A.Senior VP & CFO · born 1969
- Ms. Annette F. FavoriteChief HR Officer & Senior VP · born 1965
- Mr. Shane A. CampbellSVP & Chief Proprietary Segment Officer · born 1980
- Mr. Michel LagardePresident, CEO & Director · born 1975
- Mr. Chad R. WintersVP of Finance & Chief Accounting Officer · born 1979
- Dr. Devesh MathurSenior VP & CTO
- Mr. Norman D. Finch Jr.Senior VP, General Counsel & Corporate Secretary · born 1965
- Ms. Michele PolinskyVice President of Global Communications
- Mr. Rudy J. PoussotSenior Vice President of Strategy & Corporate Development · born 1970
- Ms. Kathy DePaduaSenior VP and Chief Quality & Regulatory Officer